Mefloquine
Tags:
drug
PubChem: 4046 4046 Related interactions
Related publications
Title
Author
Type
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Jeon, Sangeun and Ko, Meehyun and Lee, Jihye and Choi, Inhee and Byun, Soo Young and Park, Soonju and Shum, David and Kim, Seungtaek
Research
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation Mathieu Gendrot, Julien Andreani, Manon Boxberger, Priscilla Jardot, Isabelle Fonta, Marion Le Bideau, Isabelle Duflot, Joel Mosnier, Clara Rolland, Hervé Bogreau, Sébastien Hutter, Bernard La Scola, BrunoPradines
Research
Repurposing potential of FDA‐approved and investigational drugs for COVID‐19 targeting SARS‐CoV‐2 spike and main protease and validation by machine learning algorithm Akalesh Kumar Verma, Rohit Aggarwal
Research
Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor Tamim Ahsana, Abu Ashfaqur Sajib
Research
In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19 Cheryl Sachdeva, Anju Wadhwa, Anita Kumari, Firasat Hussain, Preeti Jha, Naveen K. Kaushik
Research
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Shionoya, KahoYamasaki, MasakoIwanami, ShoyaIto, YusukeFukushi, ShuetsuOhashi, HirofumiSaso, WakanaTanaka, TomohiroAoki, ShinKuramochi, KoujiIwami, ShingoTakahashi, YoshimasaSuzuki, TadakiMuramatsu, MasamichiTakeda, MakotoWakita, TakajiWatashi, Koichi
Research
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Oliver Keminer, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek
Other
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
